Juvmo (tavapadon)

Where it stands

According to the records, Juvmo (tavapadon), from AbbVie, was approved by the US FDA on 2026-09-25. The record describes it as a new medicine in tablet form. It is listed under NDA220415.

The records do not give the therapeutic area or the approved indication. This analysis therefore cannot say which patients the product is for, the approved dose, or any labeled restrictions. Readers should take those details from the FDA-approved prescribing information.

Regulatory pathway and designations

The product was approved in the US under a New Drug Application (NDA220415) and carries the designation of New molecular entity (NME). In general, an NME is an active ingredient that FDA has not previously approved in the US, either alone or in combination. NMEs are typically reviewed by FDA's drug review divisions against the standard of substantial evidence of effectiveness and a favorable benefit-risk balance.

The records show no other designations, such as Priority Review, Fast Track, Breakthrough Therapy or Orphan Drug status. They also give no submission date, PDUFA goal date or review classification, so the length and type of review cannot be assessed. No CHMP opinion is listed. That is expected for a US-region record, and the records show no EU regulatory step for this product.

Safety and pharmacovigilance

The records contain no safety information for Juvmo, such as warnings, contraindications, adverse-event data, a REMS or postmarketing commitments, so none can be assessed here.

What to watch

The records show only the approval milestone. The first step is to obtain the FDA approval letter and the final labeling to confirm the indication, dosing, warnings and any postmarketing requirements or commitments. Those documents would also show whether FDA attached further conditions to the approval.

Beyond that, the records say nothing about commercial launch timing, other regions or additional filings. Any EU or other-market regulatory activity would need to be confirmed from company or agency sources, not inferred from this US approval.